https://mindmedicinelaw.com/briefing/psilocybin-assisted-therapy-trial-launches-for-depression-in-advanced-lung-cance-20260928-45077The Psychedelic Journalen2026-09-28T22:04:52.897512+00:00Psilocybin-Assisted Therapy Trial Launches for Depression in Advanced Lung Cancer Patients (US)psilocybin-assisted therapy, lung cancer depression, clinical trial 2026, oncology psychedelics, FDA regulation, palliative care, psychedelic research, medical comorbidity, therapeutic risk, policy implicationshttps://mindmedicinelaw.com/briefing/fda-hearing-signals-shift-in-psychedelic-policy-and-oversight-20260928-44926The Psychedelic Journalen2026-09-28T15:05:30.613507+00:00FDA Hearing Signals Shift in Psychedelic Policy and Oversightfda hearing, psychedelic regulation, clinical trials, rescheduling, policy development, mdma, psilocybin, public health, risk mitigation, market accesshttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-reduces-cocaine-use-filament-health-s-exclusive-ip-pos-20260926-44834The Psychedelic Journalen2026-09-27T22:07:07.306503+00:00Psilocybin Clinical Trial Reduces Cocaine Use: Filament Health's Exclusive IP Positionpsilocybin clinical trial, cocaine use disorder, filament health, intellectual property, psychedelic research, substance use treatment, regulatory policy, exclusive data rights, public health, stimulant addictionhttps://mindmedicinelaw.com/briefing/fda-debars-jeffrey-thies-for-10-years-implications-for-drug-import-compliance-20260925-44714The Psychedelic Journalen2026-09-28T22:06:32.073665+00:00FDA Debars Jeffrey Thies for 10 Years: Implications for Drug Import Compliancefda debarment, drug import violations, psychedelic research compliance, controlled substances, supply chain risk, federal food drug and cosmetic act, clinical trial regulation, counterfeit pharmaceuticals, legal enforcement, us drug policyhttps://mindmedicinelaw.com/briefing/mapping-5-ht2-receptor-allostery-implications-for-psychedelic-drug-design-20260925-44759The Psychedelic Journalen2026-09-27T22:08:02.915304+00:00Mapping 5-HT2 Receptor Allostery: Implications for Psychedelic Drug Design5-ht2 receptor, allosteric modulation, molecular dynamics, psychedelic drug design, serotonin receptor, signaling bias, clinical trial strategy, neuropsychiatric therapeutics, ligand efficacy, drug safetyhttps://mindmedicinelaw.com/briefing/fda-psychedelic-hearing-regulatory-signals-for-u-s-psychiatry-20260925-44835The Psychedelic Journalen2026-09-27T22:07:28.145554+00:00FDA Psychedelic Hearing: Regulatory Signals for U.S. Psychiatryfda psychedelic hearing, psychiatry regulation, clinical trial guidance, psychedelic research policy, schedule i substances, prescriber training, insurance coverage psychedelics, legal risks psychedelics, public hearing fda, psychedelic therapy compliancehttps://mindmedicinelaw.com/briefing/italy-expands-landmark-psychedelic-trial-for-depression-20260925-44836The Psychedelic Journalen2026-09-27T22:07:16.418439+00:00Italy Expands Landmark Psychedelic Trial for Depressionitaly, psychedelic clinical trials, treatment-resistant depression, regulatory policy, european union, psilocybin, public health, mental health research, trial expansion, aifahttps://mindmedicinelaw.com/briefing/psychedelic-use-and-cognitive-function-insights-from-a-2026-international-study-20260924-44726The Psychedelic Journalen2026-09-28T15:05:51.467641+00:00Psychedelic Use and Cognitive Function: Insights from a 2026 International Studypsychedelic research, cognitive function, quality of life, international study, acute effects, long-term effects, policy implications, clinical trials, mental health, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-assisted-therapy-for-major-depression-evidence-and-policy-in-brazil-20260924-44762The Psychedelic Journalen2026-09-27T22:08:38.647887+00:00Psilocybin-Assisted Therapy for Major Depression: Evidence and Policy in Brazilpsilocybin, major depressive disorder, psychedelic-assisted therapy, brazil, clinical trials, antidepressant effects, policy, adverse events, regulation, mental healthhttps://mindmedicinelaw.com/briefing/ketamine-for-adolescent-trd-clinical-promise-and-safety-gaps-20260924-44776The Psychedelic Journalen2026-09-27T22:08:29.609700+00:00Ketamine for Adolescent TRD: Clinical Promise and Safety Gapsketamine, adolescent depression, treatment-resistant depression, rapid antidepressant, long-term safety, clinical trials, pediatric psychiatry, neuroplasticity, policy implicationshttps://mindmedicinelaw.com/briefing/ayahuasca-diversity-study-reshapes-policy-and-research-standards-20260924-44793The Psychedelic Journalen2026-09-27T22:08:21.138724+00:00Ayahuasca Diversity Study Reshapes Policy and Research Standardsayahuasca, botanical diversity, chemical variability, clinical trial standardization, regulatory frameworks, public health guidance, FDA, psychedelic research, harmine, DMThttps://mindmedicinelaw.com/briefing/age-moderates-psychedelic-mental-health-outcomes-new-evidence-20260924-44723The Psychedelic Journalen2026-09-27T22:08:11.850728+00:00Age Moderates Psychedelic Mental Health Outcomes: New Evidencepsychedelic research, age moderation, mental health outcomes, clinical trial design, psilocybin, LSD, regulatory guidance, public health, mystical experience, naturalistic studyhttps://mindmedicinelaw.com/briefing/global-benchmark-approved-sud-medications-2016-2026-review-20260923-44730The Psychedelic Journalen2026-09-28T15:07:24.902192+00:00Global Benchmark: Approved SUD Medications (2016–2026) Reviewsubstance use disorder medications, umbrella review, phase 3 trials, alcohol use disorder, opioid use disorder, tobacco use disorder, real-world effectiveness, policy implications, psychedelic therapy benchmark, clinical trial outcomeshttps://mindmedicinelaw.com/briefing/psilocybin-and-music-genre-emotional-effects-in-healthy-adults-20260923-44732The Psychedelic Journalen2026-09-28T15:06:59.051875+00:00Psilocybin and Music Genre: Emotional Effects in Healthy Adultspsilocybin, music genre, emotional response, clinical trial design, psychedelic therapy, set and setting, protocol optimization, healthy volunteers, affective outcomeshttps://mindmedicinelaw.com/briefing/peripheral-biomarkers-for-ketamine-response-clinical-status-and-research-gaps-20260923-44781The Psychedelic Journalen2026-09-28T15:06:37.081144+00:00Peripheral Biomarkers for Ketamine Response: Clinical Status and Research Gapsketamine, esketamine, treatment-resistant depression, peripheral biomarkers, clinical trials, inflammatory markers, BDNF, standardization, precision psychiatry, biomarker researchhttps://mindmedicinelaw.com/briefing/psychedelics-synaptic-plasticity-and-cognitive-disorders-translational-insights--20260923-44729The Psychedelic Journalen2026-09-28T15:06:14.656538+00:00Psychedelics, Synaptic Plasticity, and Cognitive Disorders: Translational Insights for Drug Developmentsynaptic plasticity, psychedelics, cognitive disorders, neuropharmacology, clinical trial design, precision medicine, bdnf, ampakines, nmda receptor modulators, biomarkershttps://mindmedicinelaw.com/briefing/fda-public-hearing-on-psychedelic-therapies-implications-for-us-policy-20260922-45078The Psychedelic Journalen2026-09-28T22:04:37.749037+00:00FDA Public Hearing on Psychedelic Therapies: Implications for US Policyfda, psychedelic therapies, public hearing, us drug policy, clinical trials, regulatory guidance, rescheduling, risk management, expanded access, post-market surveillancehttps://mindmedicinelaw.com/briefing/ketamine-guidelines-for-trd-va-dod-policy-versus-emerging-evidence-20260922-44782The Psychedelic Journalen2026-09-28T15:08:09.265612+00:00Ketamine Guidelines for TRD: VA/DoD Policy Versus Emerging Evidenceketamine, treatment-resistant depression, VA/DoD guidelines, clinical evidence, federal health policy, rapid antidepressant response, intravenous ketamine, mental health access, policy update, TRD researchhttps://mindmedicinelaw.com/briefing/psilocybin-for-treatment-resistant-depression-efficacy-and-safety-evidence-2026--20260922-44766The Psychedelic Journalen2026-09-28T15:07:47.094666+00:00Psilocybin for Treatment-Resistant Depression: Efficacy and Safety Evidence (2026 Review)psilocybin, treatment-resistant depression, clinical trials, psychedelic therapy, safety profile, efficacy, psychotherapeutic support, regulatory barriers, adverse events, long-term monitoringhttps://mindmedicinelaw.com/briefing/toxicokinetics-of-dmt-derivatives-new-human-and-zebrafish-data-20260921-44747The Psychedelic Journalen2026-09-28T22:05:21.559866+00:00Toxicokinetics of DMT Derivatives: New Human and Zebrafish Datadmt derivatives, toxicokinetics, psychedelic metabolism, forensic toxicology, clinical trial design, drug-drug interactions, novel tryptamines, zebrafish embryo model, cytochrome p450, plasma protein bindinghttps://mindmedicinelaw.com/briefing/mania-and-rhabdomyolysis-linked-to-chronic-psilocybin-use-clinical-and-policy-le-20260921-44788The Psychedelic Journalen2026-09-28T22:05:07.903477+00:00Mania and Rhabdomyolysis Linked to Chronic Psilocybin Use: Clinical and Policy Lessonspsilocybin safety, mania, rhabdomyolysis, chronic psychedelic use, dosing guidelines, adverse event reporting, public health policy, clinical trial limitations, psychedelic riskshttps://mindmedicinelaw.com/briefing/iv-ketamine-protocols-in-hospital-units-pilot-study-insights-20260921-44895The Psychedelic Journalen2026-09-28T15:08:59.098754+00:00IV Ketamine Protocols in Hospital Units: Pilot Study Insightsiv ketamine, hospital psychiatric care, pilot study, protocol implementation, public health policy, payer coverage, adverse events, multidisciplinary care, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/retraction-of-ketamine-review-alters-brain-injury-guidance-20260921-44899The Psychedelic Journalen2026-09-28T15:08:30.862406+00:00Retraction of Ketamine Review Alters Brain Injury Guidanceketamine, acute brain injury, retraction, clinical guidance, psychedelic medicine, secondary literature, peer review, neurocritical care, policy implicationshttps://mindmedicinelaw.com/briefing/first-longitudinal-study-ketamine-assisted-psychotherapy-in-youth-us-2026-20260921-44770The Psychedelic Journalen2026-09-27T22:07:40.631978+00:00First Longitudinal Study: Ketamine-Assisted Psychotherapy in Youth (US, 2026)ketamine-assisted psychotherapy, adolescents, young adults, longitudinal study, depression, suicidality, safety profile, psychedelic research, clinical trials, mental health policyhttps://mindmedicinelaw.com/briefing/chemical-restraint-in-u-s-custody-trends-outcomes-and-policy-shifts-2022-2025-20260919-44877The Psychedelic Journalen2026-09-28T22:05:32.441686+00:00Chemical Restraint in U.S. Custody: Trends, Outcomes, and Policy Shifts (2022–2025)chemical restraint, ketamine in custody, law enforcement policy, psychoactive agents, emergency medicine, civil liberties, clinical outcomes, policy reform, adverse events, oversight standardshttps://mindmedicinelaw.com/briefing/employment-risks-in-psychedelic-chronic-pain-trials-policy-and-clinical-implicat-20260918-44795The Psychedelic Journalen2026-09-28T22:05:52.416257+00:00Employment Risks in Psychedelic Chronic Pain Trials: Policy and Clinical Implicationspsychedelic clinical trials, chronic pain, employment risks, workplace drug testing, informed consent, policy implications, trial design, legal protections, participant safety, regulatory guidancehttps://mindmedicinelaw.com/briefing/chronic-ketamine-misuse-multi-organ-risks-and-clinical-gaps-20260918-44753The Psychedelic Journalen2026-09-28T22:05:42.874508+00:00Chronic Ketamine Misuse: Multi-Organ Risks and Clinical Gapsketamine misuse, multi-organ toxicity, neuropsychiatric complications, ketamine-induced uropathy, cardiac remodeling, respiratory risk, clinical management, dependence treatment gap, public health policyhttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trials-evidence-review-and-u-s-rescheduling-debate-20260918-44827The Psychedelic Journalen2026-09-27T22:07:51.796504+00:00Psilocybin Clinical Trials: Evidence Review and U.S. Rescheduling Debatepsilocybin, clinical trials, rescheduling, controlled substances act, FDA breakthrough therapy, policy implications, safety data, psychedelic therapy, regulatory frameworkshttps://mindmedicinelaw.com/briefing/ketamine-safety-in-psychosis-high-risk-groups-new-evidence-and-policy-implicatio-20260917-44818The Psychedelic Journalen2026-09-28T22:06:05.673006+00:00Ketamine Safety in Psychosis High-Risk Groups: New Evidence and Policy Implicationsketamine, psychosis risk, clinical high risk, psychedelic therapy, screening protocols, adverse events, clinical trials, public health policy, NMDA antagonist, psychiatric safetyhttps://mindmedicinelaw.com/briefing/stronger-masking-urged-in-psychedelic-trials-policy-and-research-impact-20260916-44824The Psychedelic Journalen2026-09-28T22:06:17.068446+00:00Stronger Masking Urged in Psychedelic Trials: Policy and Research Impactpsychedelic trials, masking, blinding, clinical trial design, regulatory standards, bias in research, FDA, IRB requirements, active placebo, psychedelic research